1. 4, rue Pierre Fontaine 91000 Evry France Tel: +33 (0)1 60 87 89 00 Fax: +33 (0)1 60 87 89 99 www.obetherapy.com beTherapy

2. Obesity = Difference between Energy intake & Energy expenditure (food) (metabolism & physical activity)

3. The pharmaceutical industry approach: Identify obesity genes Find molecules that are able to modulate the function of these target genes

4. They form a very complex network They are redundant and lack specificity Inhibition or activation of a single gene is compensated by other genes Problems with obesity genes:

5. Obesity genes Appetit NPY Orexin PTP-1B AGRP MG Satiety OB DB CCK POMC MCH Tubby CART Agouty FAT GLP-1 MC4R Energy Burning UCP1 UCP2 UCP3 PKA-II -Adrenergic R ACC-2 Famoxin Fat metabolism PPAR- SREBP1 C/EBPs FATPs PL (Orlistat) MTP Fat Absorption

6. Every gene Every gene involved, directly and/or indirectly in energy formation (ATP)

7. Every gene Every gene involved, directly and/or indirectly in energy formation (ATP) obesity gene is an obesity gene.

8. Every gene Every gene involved, directly and/or indirectly in energy formation (ATP) Probably several hundred genes. obesity gene is an obesity gene.

9. efficient To find efficient drugs against obesity, lipidemia and type II diabetes through innovative a completely innovative approach. Our goal

10. Our Goal: Efficiency - Our target is specific - Its function is not redundant - Efficiency - No side effect

11. Slimness Slimness gene as new target for the treatment of obesity, lipidemia and type II diabetes

12. Is there any genetic disease in which the phenotype is : lean, low cholesterol and low triglycerides ? Our strategy A single gene with a tissue specific expression

13. From a particular case (slim phenotype) To treat general obesity cases

14. Advantages of our anti-obesity target versus competitor targets Specificity - Specific function - Tissue specific expression (intestine) Non Redundant

15. Current Situation A first therapeutic target validated Patent pending A list of potential hit compounds obtained by virtual screening Patent pending A patented HTS assay design for our first target

16. Next steps In-vitro and cellular testing hit compounds In-vivo testing for best leads Clinical Study phase I first Q1 2004 HTS for new hit compounds Transgenic rabbits dominant/negative and/or RNAi Polymorphism of other candidat genes Enhance the value of the company and reduce the risks to investors in order to attract Venture Capital

17. Slimness genes allow you to eat without gaining weight.

18. Nature did it,

19. Slimness genes allow you to eat without gaining weight. Nature did it, can reproduce it.